Login
$SVRA
$4.66 +$0.20 (4.37%) After hours

$SVRA 8-K SEC Filings

Filed On Filing
08 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more

Savara Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify that:

13 Mar 2026 8-K: Entry into a Material Definitive Agreement

THIS AGREEMENT OF LEASE, made as of the 10th day of March 2026, by and between ML7 YARDLEY PARTNERS, LP, a Pennsylvania limited partnership (“Landlord”) and SAVARA INC., a Delaware corporation (“Tenant”).

27 Jan 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

On January 26, 2026, Savara Inc. (the “Company”) entered into a First Amendment (the “First Amendment”) to the Loan and Security Agreement, dated March 26, 2025 (the “Loan Agreement”), with the lenders party thereto (the “Lenders”) and H...

09 Jan 2026 8-K: Regulation FD Disclosure

Corporate Overview January 2026 Developing new therapies for rare respiratory diseases Exhibit 99.1

30 Oct 2025 8-K: Entry into a Material Definitive Agreement; Other Events

Introductory. Savara Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of 23,809,524 shares (the “Firm Shares”) of its common st...

29 Oct 2025 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more

Corporate Overview October 2025 © Savara Inc. All Rights Reserved. Exhibit 99.2

02 Sep 2025 8-K: Regulation FD Disclosure

Corporate Overview Developing New Therapies for Rare Respiratory Diseases September 2025 © Savara Inc. All Rights Reserved. Exhibit 99.1

06 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

At the annual meeting of stockholders of Savara Inc. (“Savara”) held on June 5, 2025 (the “Annual Meeting”), our stockholders elected each of the following individuals to serve on the Board of Directors until the next annual meeting of s...

27 May 2025 8-K: Other Events

LANGHORNE, Pa. — May 27, 2025 — Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced that the Company received an RTF letter from the FDA for the BLA o...

31 Mar 2025 8-K: Termination of a Material Definitive Agreement

As previously disclosed, on July 6, 2021, Savara Inc. (the “Company”) entered into a Sales Agreement with Evercore Group L.L.C. (“Evercore”), as sales agent (the “ATM Agreement”), pursuant to which the Company may offer and sell up to an...

26 Mar 2025 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +2 more

— Includes $30M at Close to Refinance Existing Debt Facility —

23 Jan 2025 8-K: Departure/Election of Directors or Officers; Compensation

On January 17, 2025, upon the recommendation of the Compensation Committee of the Board of Directors (the “Board”) of Savara Inc. (“Savara”), the Board approved the target bonus amounts for Savara’s executive officers for the year ended ...

13 Jan 2025 8-K: Regulation FD Disclosure

Exhibit 99.1 Corporate Overview Developing New Therapies for Rare Respiratory Diseases January 2025 © Savara Inc. All Rights Reserved.

28 Jun 2024 8-K: Entry into a Material Definitive Agreement; Other Events

Introductory. Savara Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 26,246,720 shares (the “Shares”) of its common stock, par ...

26 Jun 2024 8-K: Regulation FD Disclosure; Other Events

SAVARA ANNOUNCES MOLGRAMOSTIM NEBULIZER SOLUTION (MOLGRAMOSTIM) ACHIEVED STATISTICAL SIGNIFICANCE FOR PRIMARY ENDPOINT AND MULTIPLE SECONDARY ENDPOINTS IN IMPALA-2, A PIVOTAL PHASE 3 CLINICAL TRIAL IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEI...

07 Jun 2024 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders

Savara Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify that:

12 Apr 2024 8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation +1 more

The information included in Item 8.01 is incorporated by reference into this Item 1.01 to the extent applicable.

16 Feb 2024 8-K: Entry into a Material Definitive Agreement

On February 13, 2024, Savara Inc. (the “Company”) entered into a Master Services Agreement (the “Agreement”) with Fujifilm Diosynth Biotechnologies UK Limited, Fujifilm Diosynth Biotechnologies Texas, LLC, and Fujifilm Diosynth Biotechno...

25 Jan 2024 8-K: Departure/Election of Directors or Officers; Compensation

On January 24, 2024, upon the recommendation of the Compensation Committee of the Board of Directors (the “Board”) of Savara Inc. (“Savara”), the Board approved the target bonus amounts for Savara’s executive officers for the year ended ...

05 Jan 2024 8-K: Regulation FD Disclosure

Exhibit 99.1 Corporate Overview Developing New Therapies for Rare Respiratory Diseases January 2024

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support